Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving trastuzumab together with gefitinib works in
treating patients with HER2-positive breast cancer. The monoclonal antibody trastuzumab can
locate breast cancer cells that have HER2 on their surface and either kill them or deliver
tumor-killing substances to them without harming normal cells. Biological therapies such as
gefitinib may also interfere with the growth of tumor cells and may enhance the effects of
trastuzumab. Combining trastuzumab with gefitinib may be an effective treatment for
metastatic breast cancers with high amounts of HER2